TransMedics Group (TMDX) Gets a Buy Rating from Oppenheimer
In a report released today, Suraj Kalia from Oppenheimer maintained a Buy rating on TransMedics Group (TMDX), with a price target of $60.00. The company’s shares closed last Tuesday at $26.72.
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 8.7% and a 56.0% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Inspire Medical Systems, and Cardiovascular Systems.
Currently, the analyst consensus on TransMedics Group is a Strong Buy with an average price target of $56.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $49.50 and a one-year low of $11.51. Currently, TransMedics Group has an average volume of 963.6K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.